Abstract
The term platelet-activating factor (PAF) proposed by Benveniste et al. (1972) was originally designed to indicate the primary biological properties of a novel substance released from basophils upon IgE stimulation. This factor was later identified independently by three separate groups (Benveniste et al., 1979; Blank et al., 1979; Demopoulos et al., 1979) to be l-O-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine. This novel group of compounds was rapidly recognized to have diverse biological actions, far beyond those originally shown on platelets. It also became apparent that PAF can be synthesized and released from a multitude of cells and organs by immune and nonimmune stimuli (Benveniste and Chignard, 1985; Snyder, 1985; Vanhoutte and Houston, 1985; Zimmerman et al., 1985).
Keywords
- Left Anterior Descend
- Platelet Activate Factor
- Platelet Activate Factor Antagonist
- Femoral Artery Blood Flow
- Left Anterior Descend Flow
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Adnot, S., Lefort, J., Lagent, V., Braquet, P., Vargaftig, B. B., 1986, Interference of BN 52021, a PAF-acether antagonist, with endotoxin induced hypotension in the guinea pig,Pharmacol. Rev. 18:197–200.
Archer, C. B., Page, C. P., Paul, W., Morley, J., and McDonald, D. M., 1983, Early and late inflammatory effects of PAF-acether in the skin of experimental animals and man,J. Invest. Dermatol. 80:346–347.
Archer, C. B., Frohlich, W., Page, C. W., Paul, W., Morley, J., and McDonald, D. M., 1984, Synergistic interaction between prostaglandins and PAF-acether in experimental animals and man,Prostaglandins27:495–501.
Baranes, J., Helleganarch, A., Le Hegarat, M., Viossat, I., Auguet, M., Chabrier, P. E., Clostre, F., and Braquet, P., 1986, The effect of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021,Pharmacol. Res. Commun. 8:717–737 (Feb.).
Benveniste, J., and Chignard, M., 1985, A role for PAF-acether (platelet activating factor) in platelet-dependent vascular diseases,Circulation72:713–717.
Benveniste, J., Henson, P. M., and Cochrane, C. G., 1972, Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor,J. Exp. Med. 136:1356–1377.
Benveniste, J., Tence, M., Varenne, P., Bidault, J., Boullet, C., and Polonsky, J., 1979, Semi-synthese et structure purposee du facteur activant les plaquettes (PAF); PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine,C. R. Acad. Sci. Ser. D289:1037–1040.
Benveniste, J., Boullet, C., Brink, C., and Labat, C., 1983, The action of PAF-acether (platelet activating factor) on guinea pig isolated heart preparations,Br. J. Pharmacol. 80:81–83.
Bessin, P., Bonnet, J., Apffel, D., Soulard, C., Desgroux, L., Plas, I., and Benveniste, J., 1983, Acute circulatory collapse caused by platelet activating factor (PAF-acether) in dogs,Eur. J. Pharmacol. 86:403–413.
Bjork, J., and Smedegard, G., 1983, Acute microvascular effects of PAF-acether as studied by intravital microscopy,Eur. J. Pharmacol. 96:87–94.
Blank, M. L., Snyder, F., Byers, L. W., Brooks, B., and Muirhead, E. E., 1979, Antihypertensive activity of an alkyl ether analog of phosphatidylcholine,Biochem. Biophys. Res. Commun. 90:1194–1200.
Blank, M. L., Cress, E. A., Lee, T.-C., Malone, B., Surles, J. R., Piantadosi, C., Hajdu, J., and Snyder, F., 1982, Structural features of platelet activating factor (l-alkyl-2-acetyl-sn-glycero-3-phosphocholine) required for hypotensive and platelet serotonin responses,Res. Commun. Chem. Path. Pharmacol. 38:3–20.
Blank, M. L., Hall, M. N., Cress, E. A., and Snyder, F., 1983, Inactivation of l-alkyl-2-acetyl-sAi-glycero-3-phosphocholine by a plasma acetylhydrolase: Higher activities in hypertensive rats,Biochem. Biophys. Res. Commun. 113:666–671.
Blankley, C. J., and Kaplan, H. R., 1984, Biologically active phospholipids as potential cardiovascular drugs,Drug Dev. Res. 4:351–372.
Bonnet, J., Loiseau, A. M., Orvoen, M., and Bessin, P., 1981, Platelet activating factor acether (PAF-acether) involvement in acute inflammatory and pain processes,Agents Actions11:559–562.
Bourgain, R. H., Maes, L., Braquet, P., Andries, R., Touqui, L., and Braquet, M., 1985, The effect of l-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF-acether) on the arterial wall,Prostaglandins30:185–197.
Boyd, L. M., Ezra, D., Feuerstein, G., and Goldstein, R. E.. 1983, Effect of FPL 55712 or indo-methacin on leukotriene-induced coronary constriction in the intact pig heart,Eur. J. Pharmacol. 89:307–311.
Braquet, P., Vidal, R. F., Hamard, H., and Vargaftig, B. B., 1984, Involvement of leukotrienes and PAF acether in the increased microvascular permeability of rabbit retina,Agents Actions15:82–85.
Braquet, P., Etienne, A., Touvay, C., Bourgain, R. H., Lefort, J., and Vargaftig, B., 1985a, Involvement of platelet-activating factor in respiratory anaphylaxis demonstrated by PAF-acether inhibitor BN 52021,Lancet I8444:1501.
Braquet, P., Spinnewyn, B., Braquet, M., Bourgain, R. H., Taylor, J. E., Nunez, D., and Drieu, K., 1985b, BN 52021 and related compounds: A new series of highly specific PAF-acether receptor antagonsts isolated fromGinkgo biloba, Blood Vessels(in press).
Caillard, C. G., Mondot, S., Zundel, J. L., and Julou, L., 1982, Hypotensive activity of PAF-acether in rats,Agents Actions12:725–730.
Camussi, G., Aglietta, M., Malavasi, F., Tetta, C., Piacibello, W., Sanavio, F., and Bussolino, F., 1983, The release of platelet activating factor from human endothelial cells in culture,J. Immunol. 131:2397–2403.
Camussi, G., Alloatti, G., Montrucchio, G., Meda, M., and Emanuelli, G., 1984, Effect of platelet activating factor on guinea pig papillary muscle,Experientia40:697–699.
Cervoni, P., Herzlinger, H. E., Lai, F. M., and Tanikella, T. K., 1983, Aortic vascular and atrial responses to (±)-l-0-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine,Br. J. Pharmacol. 79:667– 671.
Cervoni, P., Goldstein, B. M., Herelinger, H., Lai, F. M., and Quirk, G. J., 1984, Evidence for the lack of interaction between (//-)-l-0-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine and a-adrenocep-tors in vivo and in vitro,Br. J. Pharmacol. 83:511–517.
Demopoulos, C. A., Pinckard, R. N., and Hanahan, D. J., 1979, Platelet activating factor: Evidence for l-0-alkyl-2-acetyl-s«-glyceryl-3-phosphorylcholine as the active component (a new class of liquid chemical mediator),J. Biol. Chem. 254:9355–9358.
Doebber, T. W., Wu, M. S., Robbins, J. C., Choy, B. M., Chang, M. N., and Shen, T. Y., 1985, Platelet activating factor (PAF) involvement in endotoxin induced hypotension in rats. Studies with PAF receptor antagonist kadsurenone,Biochem. Biophys. Res. Commun. 127:799–808.
Etienne, A., Hecquet, F., Soulard, C., Spinnewy, B., Clostre, F., and Braquet, P., 1985, In vivo inhibition of plasma protein leakage andSalmonella enteritidisinduced mortality in the rat by a specific PAF-acether antagonist BN 52021,Agents Actions17(3–4):368–370.
Farber, J. E., Barron, K. W., Bonham, A. C., Lappe, R., Muirhead, E. E.. and Brody, M. J., 1984, Regional hemodynamic effects of antihypertensive renomedullary lipids in conscious rats,Hypertension6:494–502.
Feuerstein, G., 1984, Leukotrienes and the cardiovascular system.Prostaglandins27:781–802.
Feuerstein, G., 1985, Autonomic pharmacology of leukotrienes,J. Anton. Pharmacol. 5:149–168.
Feuerstein, G., Zukowska-Grojec, Z.. Krausz, M. M., Blank, M. L., Snyder, F., and Kopin, I. J., 1982, Cardiovascular and sympathetic effects of l-0-hexadecyl-2-acetyl-sn-glycero-3-phos-phocholine in conscious SHR and WKY rats,Clin. Exp. Hypertens. [A]4:1335–1350.
Feuerstein, G., Boyd, L. M., Ezra, D., and Goldstein, R. E., 1984, Effect of platelet activating factor on coronary circulation of the domestic pig.Am. J. Physiol. 246:H466–H471.
Feuerstein, G.. Ezra. D., Ramwell. P. W., Letts. G.. and Goldstein. R. E.. 1985a. Platelet activating factor as a modulator of cardiac and coronary functions, in:Prostaglandins, Leukotrienes and Lipoxins(J. M. Bailey, ed.), Plenum, New York, pp. 301–310.
Feuerstein, G., Lux, W. E., Ezra, D., Hayes, E. C., Snyder, F., and Faden, A. I., 1985b, Thyrotropin releasing hormone blocks the hypotensive effects of platelet activating factor in the unanesthetized guinea pig,J. Cardiovasc. Pharmacol. 7:335–340.
Foegh, M. L., Khirabadi, B. S., Rowles, J., Braquet, P., and Ramwell, P. W., 1985, Prolongation of rat cardiac allograft survival with BN 52021 a specific antagonist of platelet activating factor,Transplantation42(l):86–88.
Goldstein, B. M., Gabel, R. A., Huggins, F. J., Cervoni, P., and Crandall, D. L., 1984, Effect of platelet activating factor (PAF) on blood flow distribution in the spontaneously hypertensive rat,Life Sci. 35:1373–1378.
Gothberg, G., Lundin, S., and Folkow, B., 1978, Acute vasodepressor effect in normotensive rats following extracorporeal perfusion of the declipped kidney of two kidney, one clip hypertensive rats,Clin. Sci. Mol. Med. 54:361–367.
Grandel, K. E., Farr, R. S., Wanderer, A. A., Eisenstadt, T. C., and Wasserman, S. I., 1985, Association of platelet activating factor with primary acquired cold urticaria,N. Engl. J. Med. 313:405–409.
Grollman, A., and Rule, C., 1943, Experimental induced hypertension in parabiotic rats.Am. J. Physiol. 138:587–592.
Humphrey, D. M., Hanahan, D. J., and Pinckard, R. N., 1982a, Induction of leukocytic infiltrates in rabbit skin by acetyl glycerl ether phosphorylcholine,Lab. Invest. 47:227–234.
Humphrey, D. M., McManus, L. M., Satouchi, K., Hanahan, D. J., and Pinckard, R. N., 1982b, Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues,Lab. Invest. 46:422–427.
Inarrea, P., Alonso, F., and Sanchez-Crespo, M., 1983, Platelet activating factor: An effector substance of vasopermeability changes induced by the infusion of immune aggregates in the mouse,Immu-nopharmacology6:7–14.
Inarrea, P., Gomez-Cambronero, J., Pascual, J., Carmen-Ponte del, M., Hernando, L., and Sanchez-Crespo, M., 1985, Synthesis of PAF-acether and blood volume changes in Gram negative sepsis,Immunopharmacology9:45–52.
Jackson, C. V., Driscoll, E. M., Pope, T. K., and Lucchesi, B. R., 1985, PAF in platlet-mediated coronary artery vasodilation,Circulation72 (Pt. I, No. 4): 190 (abstract).
Kenzora, J. L., Perez, J. E., Bergmann. S. R.. and Lange, L.. 1984, Effects of acetyl glyceryl ether phosphorylcholine (platelet activating factor) on ventricular preload, afterload and contractility in dogs,J. Clin. Invest. 74:1193–1203.
Lai, F. M., Shepherd, C. A., Cervoni, P., and Wissner, A., 1983, Hypotensive and vasodilatory activity of (H-)l-0-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine in the normotensive rats,Life Sci. 32:1159–1166.
Laurindo, F. R. M., Ezra, D., Czaja, J. F., Feuerstein, G., and Goldstein, R. E., 1985a, Acute right ventricular failure due to platelet activating factor or thromboxane A2 analog,Clin. Res. 33:203A (abstract).
Laurindo, F. R. M., Ezra, D., Feuerstein, G., and Goldstein, R. E., 1985b, Spontaneous escape from coronary constriction due to thromboxane A2 analog infusion,Clin. Res. 33:204A (abstract).
Levi, R., Burke, J. A., Guo, Z. G., Hattori, Y., Hoppens, C. M., McManus, L. M., Hanahan, D. J., and Pinckard, R. N., 1984, Acetyl glyceryl ether phosphorycholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig,Circ. Res. 54:117–124.
Lux, W. E., Feuerstein, G., and Faden, A. I., 1983a, Thyrotropin releasing hormone reverses experimental anaphylactic shock through non-endorphin related mechanism,Eur. J. Pharmacol. 90:301-302.
Lux, W. E., Feuerstein, G., and Faden, A. I., 1983b, Thyrotropin releasing hormone reverses the hypotension and bradycardia produced by leukotriene D4 in unanesthetized guinea pigs,Prostaglandins Leukotrienes Med. 10:301–307.
Lux, W. E., Feuerstein, G., and Faden, A. I., 1983c, Alteration of leukotriene D4 hypotension by thyrotropin releasing hormone,Nature302:822–824.
Manger, W. M., Van Praag, D., Weiss, D. J., Hart, C. J., Hulse, M., Rock, T. W., and Farber, S. J., 1976, Effect of transplanting renomedullary tissue into spontaneously hypertensive rats (SHR),Fed. Proc. 35:556.
McManus, L. M., Hanahan, D. J., Demopoulos, C. A., and Pinckard, R. N., 1980, Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet activating factor (PAF) in the rabbit,J. Immunol. 124:2919–2924.
Muirhead, E. E., 1980, Antihypertensive functions of the kidney,Hypertension2:444–464.
Muirhead, E. E., Brooks, B., Pitcock, J. A., and Stephenson, P., 1972a, Renomedullary antihypertensive function in accelerated (malignant) hypertension: Observations on renomedullary interstitial cells,J. Clin. Invest. 51:181–190.
Muirhead, E. E., Brooks, B., Pitcock, J. A., Stephenson, P., and Brosius, W. L., 1972b, Role of the renal medulla in the sodium sensitive component of renoprival hypertension,Lab. Invest. 27:192-198.
Murihead, E. E., Germain, G. S., Leach, B. E., Brooks, B., and Stephenson, R., 1973, Renomedullary interstitial cells (RIC), prostaglandins (PG) and the antihypertensive function of the kidney,Prostaglandins3:581–594.
Muirhead, E. E., Rightsel, W. A., Leach, B. E., Byers, L. W., Pitcock, J. A., and Brooks, B., 1977, Reversal of hypertension by transplants and lipid extracts of cultured renomedullary interstitial cells,Lab. Invest. 36:162–172.
Muirhead, E. E., Byers, L. W., Desiderio, D., Smith, K. A., Prewitt, R. L., and Brooks, B., 1981a, Alkyl ether analogs of phosphatidylcholine are orally active in hypertensive rabbits,Hypertension3:I107-I111.
Muirhead, E. E., Byers, L. W., Desiderio, D., Brooks, B., and Brosius, W. M., 1981b, Antihypertensive lipids from the kidney: Alkyl ether analogs of phosphatidylcholine,Fed. Proc. 40:2285–2290.
Muirhead, E. E., Folkow, B., Byers, L. W., Desiderio, D. M., Thoren, P., Gothberg, G., Dow, A. W., and Brooks, B., 1983, Cardiovascular effects of antihypertensive polar and neutral renomedullary lipids,Hypertension(Suppl 1) 5:1112–1118.
Namm, D. H., Tadepalli, A. S., and High, J. A., 1982, Species specificity of the platelet response to l-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine,Thromb. Res. 25:341–350.
Otsuka, A., Masugi, F., Ogihara, T., Saeki, S., Nagano, M., Koyama, Y., Tabuchi, Y., andKumahara, Y., 1985, Hypotensive mechanism of acetyl glyceryl ether phosphorylcholine (AGEPC) in dogs. Effects on hemodynamics and humoral factors,Prostaglandins Leukotrienes Med. 19:25–35.
Pinckard, R. M., Kniker, W. T., Lee, L., Hanahan, D. J., and McManus, L. M., 1980, Vasoactive effects of l-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AGEPC) in human skin,J. Allergy Clin. Immunol. 65:196.
Piper, P. J., 1985, Leukotrienes, PAF and the heart. Proceedings of the Symposium “Leukotrienes et PAF-acether,” Societe de Pharmacologie Experimentale, Paris (Abstract).
Pirotzky, E., Page, C. P., Roubin. R., Pfister, A., Paul, W.. Bonnet, J., and Benveniste, J.. 1984, PAF-acethcr induced plasma extravasation in rat skin is independent of platelets and neutrophils,Micro. Endoth. Lymph. 1:107–122.
Prevost, M. C. Cariven, C. Simon, M. F.. Chap, H.. and Douste Blazy, L., 1984, Platelet activating factor (PAF-acether) is released in rat pulmonary alveolar fluid as a consequence of hypoxia,Biochem. Biophys. Res. Commiin. 119:58–63.
Prewitt, R. L.. Leach. B. E., Byers, L. W.. Brooks, B., Lands, W. E., and Muirhead, E. E., 1979. Antihypertensive polar renomedullary lipid: A semisynthetic vasodilator.Hypertension1:299–308.
Saeki, S., Masugi, F., Ogihara, T.. Otsuka, A.. Kumahara. Y., Watanabe. K., Tamura, K., Akashi, H., and Kumagai. A., 1985, Effects of l-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on cardiac function in perfused guinea pig heart.Life Sci. 37:325–330.
Sanchez-Crespo. M.. Alonso, F., Inarrea, P., Alvarez. V., and Egido. J., 1982, Vascular actions of synthetic PAF-acether (a synthetic platelet activating factor) in the rat: Evidence for a platelet independent mechanism,lmmunopharmacology4:173–185.
Sanchez-Crespo. M., Fernandez Gallardo, S., Nieto, M. L., Baranes, J., and Braquet, P., 1985, Inhibition of the vascular actions of IgG aggregates by BN 52021, a highly specific antagonist of PAF-acether,lmmunopharmacology10:69–75.
Shen, T. Y., Hwang, S. B., Chang, M. N., Doebber, T. W., Lam, M. H., Wu. M. S., Wang, X., Han, G. Q.. and Run, Z. L.. 1985, Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng(Piper futokadsura): Specific inhibition ofin vitroandin vivoplatelet-activating factor-induced effects,Proc. Natl. Acad. Sci. USA82:672–676.
Smith, K. A., Prewitt, R. L., Byers, L. W., and Muirhead, E. E., 1981, Analogs of phosphatidylcholine: a-Adrenergic antagonists from the renal medulla,Hypertension3:460–470.
Snyder, F., 1985. Chemical and biochemical aspects of platelet activating factor: A novel class of acetylated ether-linked choline phospholipids,Medicinal Res. Rev. 5:107–140.
Stimler, N. P., Bloor, C. M.,Hugli.T. E.. Wykle. R. L.. McCall, C. E.. and O’Flaherty, J. T.. 1981, Anaphylactic actions of platelet activating factor.Am. J. Pathol. 105:64–69.
Sun, F. F., and McGuire, J. C., 1983, Inhibition of human neutrophil arachidonate 5-lipoxygenase by 6,9-deepoxy-6,9-/V-(phenylimino)--6.8-prostaglandin I1, (U-60257),Prostaglandins36:211–221.
Sybertz, E. J., Watkins, R. W., Baum, T., Pula, K., and Rivelli, M., 1985, Cardiac, coronary and peripheral vascular effects of acetyl glyceryl phosphoryl choline in the anesthetized dog,J. Phar macol. Exp. Ther. 232:156–162.
Terashita, Z. I., Tsushima, S., Yoshioka, Y., Nomura, H., Inada, Y., and Nishikawa, K., 1983, CV-3988-A specific antagonist of platelet activating factor (PAF),Life Sci. 32:1975–1982.
Terashita, Z. I., Imura. Y., Nishikawa, K., and Sumida, S., 1985, Is platelet activating factor (PAF) a mediator of endotoxin shock,Eur. J. Pharmacol. 109:257–261.
Vanhoutte, P. M., and Houston, D. S., 1985. Platelets, endothelium and vasospasm,Circulation72:728–734.
Vargaftig, B. B., Lefort, J., Chignard, M., and Benveniste, J., 1980, Platelet activating factor induces a platelet dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives,Eur. J. Pharmacol. 65:185–192.
Vemulapalli, S., Chiu, P. J., and Barnett, A., 1984, Cardiovascular and renal action of platelet activating factor in anesthetized dogs,Hypertension6:489–493.
Voelkel, N. F., Worthen, S., Reeves, J. T., Henson, P. M., and Murphy, R. C, 1982, Nonim-munological production of leukotrienes induced by platelet-activating factor,Science218:286–289.
Weisman, S. M., Felson, D., and Vaughan, E. D., 1985, Platelet activating factor is a potent stimulus for renal prostaglandin synthesis. Possible significance in unilateral ureteral obstruction,J. Pharmacol. Exp. Ther. 235:10–15.
Young, J. M., Maloney, P. J., Jubb, S. N., and Clark, J. S., 1985, Pharmacological investigation of the mechanism of platelet activating factor induced mortality in the mouse,Prostaglandins30:545–551.
Zimmerman, G. A., McIntyre, T. M., and Prescott, S. M., 1985, Production of platelet activating factor by human vascular endothelial cells: Evidence for a requirement for specific agonists and modulation by prostacyclin,Circulation72:718–727.
Zukowska-Grojec, Z., Blank, M. L., Snyder, F., and Feuerstein, G., 1985, The adrenergic system and the cardiovascular effects of platelet activating factor (l-0-hexadecyl-2-acetyl-sn-glycero-3-phos-phocholine) in SHR and WKY rats,Clin. Exp. Hypertens. [A]7:1015–1031.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Plenum Press, New York
About this chapter
Cite this chapter
Feuerstein, G., Goldstein, R.E. (1987). Effect of PAF on the Cardiovascular System. In: Snyder, F. (eds) Platelet-Activating Factor and Related Lipid Mediators. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5284-6_19
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5284-6_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5286-0
Online ISBN: 978-1-4684-5284-6
eBook Packages: Springer Book Archive